Get started

MiNK Therapeutics (United States)

Alternate name: MiNK Therapeutics
ROR: 04n7wdr86
OpenAlex ID: I4405265386
Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024 · Dhan Chand, David A. Savitsky, et al. · Cancer Discovery · 60
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome
2024 · Terese C. Hammond, Marco A. Purbhoo, et al. · Nature Communications · 48
PDF
CAR-iNKT cells: redefining the frontiers of cellular immunotherapy
2025 · Magdalena Niedzielska, Amy Chalmers, et al. · Frontiers in Immunology · 29
PDF
Innate iNKT cells: from biological insight to clinical impact
2025 · Antonia Rotolo, Nicola J. Mason, et al. · Frontiers in Immunology · 14
PDF
Abstract CT275: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors
2023 · Benedito Carneiro, Benjamin Garmezy, et al. · Cancer Research · 13
470 Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors
2022 · Chloe Delepine, Daniel Levey, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
2025 · Benjamin Garmezy, Joseph E. Grossman, et al. · Oncogene · 10
PDF
The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2025 · Eleni Chantzoura, Efrat Altman-Sharoni, et al. · Cancer Immunology Research · 5
Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model
2022 · Bindu Varghese, Lydia Lynch, et al. · Cancer Immunology Immunotherapy · 5
647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma
2022 · Don Stevens, Clifton Mo, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer
2023 · Jamie Moon, Sue Ryu, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
649 Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19)
2022 · Marco Purbhoo, Burcu Yigit, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
10-Year Real-World Data on Acute Myeloid Leukemia: The Paradigm of a Public Health Center in Brazil
2024 · Camilla Campos, Alini Maria Orathes Ponte Silva, et al. · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY · 2
753 AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and/or bi-specific engagers to improve anti-cancer response
2024 · Martyna Popis, Efrat Altman Sharoni, et al. · Journal for ImmunoTherapy of Cancer · 2
374 PRAME-TCR iNKT cell therapy: opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME
2024 · Paul Ibbett, Marc Van Dijk, et al. · Journal for ImmunoTherapy of Cancer · 2
Persistent SARS-CoV-2 Viremia, COVID-19 Associated Acute Respiratory Distress Syndrome, Severe Coagulopathy and Massive Hemoptysis in a Renal Transplant Patient on Veno-Venous Extracorporeal Membrane Oxygenation
2024 · T.C. Hammond, C.L. Channick, et al. · American Journal of Respiratory and Critical Care Medicine · 2
358 Development of an allogenic FAP CAR iNKT product to target tumor stroma and modulate the tumor microenvironment
2022 · Xavier Michelet, Martyna Popis, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
372 agenT-797, a native allogeneic “off-the-shelf” invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment
2022 · Sapana Pokharel, John Chamberland, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
270 AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
2026 · Shanmugarajan Krishnan, Bishnu Joshi, et al. · Journal for ImmunoTherapy of Cancer
PDF
177 Native and engineered allogenic invariant natural killer T (iNKT) cells eliminate senescent tumor cells and fibroblasts in oncogenic in vitro models
2026 · Jing Fang, Yan Sun, et al. · Journal for ImmunoTherapy of Cancer
PDF
D107-03 Novel Interleukin-15 Superagonist (n-803) and Invariant Natural Killer T Cell (agent-797) Combination Immunotherapy for Unresolving Coccidioides Immitis Infection
2026 · T C Hammond, M Purbhoo, et al. · American Journal of Respiratory and Critical Care Medicine
Rapid suppression of unresolving disseminated coccidioidomycosis infection with combined IL-15 super-agonist (N-803) and invariant natural killer T cell therapy
2026 · Terese C. Hammond, Marco A Purbhoo, et al. · Clinical Immunology Communications
1344 AgenT-797, an allogeneic iNKT cell therapy, demonstrates durable clinical activity in solid tumors: updated phase 1 findings
2025 · Marco A Purbhoo, Thiago Favano, et al. · Journal for ImmunoTherapy of Cancer
PDF
Challenges to achieving BMT in the treatment of AML in Brazil: Bahia University Hematology Center experience
2023 · Felipe Feistauer, Marco Salvino, et al. · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Safe Administration of Novel Allogeneic iNKT Cell Infusion to Four Patients With Severe COVID-19 Respiratory Failure (CARDS) Receiving Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support
2023 · T.C. Hammond, M.A. Purbhoo, et al. · American Journal of Respiratory and Critical Care Medicine
Works count: 28
Citation count: 1,374
Year
Topic
Type